AbbVie Stock Dips 035% with 884 Billion Trading Volume Ranking 94th in Market Activity

On June 9, 2025, AbbVie (ABBV) experienced a slight decline of 0.35% in its stock price, with a trading volume of 8.84 billion, ranking 94th in the day's market activity.

AbbVie's presence at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 was notable for its innovative and authentic booth design. The company's booth featured a "dream space" where visitors could express gratitude, with thank-you messages turning into lights that displayed on a starry night sky. This interactive experience was well-received, enhancing AbbVie's brand image and engagement with attendees.

During the ASCO meeting, AbbVie showcased significant breakthroughs in its antibody-drug conjugate (ADC) pipeline. The company presented data on telisotuzumab adizutecan, which achieved an overall response rate (ORR) of 63% in EGFR-mutant non-small cell lung cancer (NSCLC). This data highlights AbbVie's potential in the NSCLC market and underscores the company's advancements in oncology treatments.